From Precision press release (my emphasis in bold):
" Imugene will assume ongoing clinical execution for azer-cel in the large B-cell lymphoma (LBCL) population who have relapsed following autologous CAR T treatment. The license also includes an option to develop up to three other cancer research programs in the future."; and
"For azer-cel, Precision is eligible to receive up to $198 million in additional milestone payments and double-digit royalties on net sales. For each additional research program selected by Imugene, Precision is eligible for up to $145 million in milestone payments and tiered royalties on net sales."
Thats about $1 billion AUD in milestone payments if Imugene exercise the additional 3 programs, plus royalties on all programs.
From Precision press release (my emphasis in bold): " Imugene...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.5¢ |
Change
0.001(1.19%) |
Mkt cap ! $622.1M | |||
| Open | High | Low | Value | Volume |
| 8.3¢ | 8.6¢ | 8.2¢ | $1.062M | 12.66M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 495709 | 8.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.5¢ | 919740 | 6 |
View Market Depth
| Last trade - 16.10pm 02/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.4¢ |
Change
0.001 ( 0.84 %) |
||||
| Open | High | Low | Volume | ||
| 8.4¢ | 8.6¢ | 8.2¢ | 6843386 | ||
| Last updated 15.59pm 02/05/2024 ? | |||||
| IMU (ASX) Chart |